(Q38274802)

1 September 2017

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis (English)

1 reference

1 September 2017

0 references

1 reference

Kwaan HC

1

1 reference

1 September 2017

Wang J

series ordinal

2

1 reference

1 September 2017

Svoboda K

series ordinal

3

1 reference

1 September 2017

Declerck PJ

series ordinal

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

British Journal of Cancer

1 September 2017

1 reference

1 September 2017

82

1 reference

1 September 2017

10

1 reference

1 September 2017

1702-1708

1 reference

Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor

1 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

The plasminogen-plasmin system in malignancy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Plasminogen activators, tissue degradation, and cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

The urokinase-type plasminogen activator system in cancer metastasis: a review

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374508

Conformational Studies on Plasminogen Activator Inhibitor (PAI-1) in Active, Latent, Substrate, and Cleaved Forms

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1054%2FBJOC.2000.1207

Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer

21 January 2018

1 reference

12 December 2020

Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer

1 reference

12 December 2020

Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis

1 reference

12 December 2020

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

1 reference

12 December 2020

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis

1 reference

12 December 2020

Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus

1 reference

12 December 2020

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

1 reference

12 December 2020

Identification of the urokinase receptor as an adhesion receptor for vitronectin

1 reference

12 December 2020

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy

1 reference

12 December 2020

The urokinase receptor is a major vitronectin-binding protein on endothelial cells

1 reference

12 December 2020

Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma

1 reference

12 December 2020

Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms

1 reference

12 December 2020

Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility

1 reference

12 December 2020

Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2000.1207

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference

1 September 2017

PubMed publication ID

10817507

1 reference